Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 226Neoplasms 195Prostatic Neoplasms 164Multiple Myeloma 140Neoplasm Metastasis 117Melanoma 113Colorectal Neoplasms 108Leukemia, Myeloid, Acute 107Lung Neoplasms 98Lymphoma 97Ovarian Neoplasms 87Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 65Triple Negative Breast Neoplasms 64Pancreatic Neoplasms 64Hematologic Neoplasms 60Parkinson Disease 4, Autosomal Dominant Lewy Body 59Head and Neck Neoplasms 59Glioblastoma 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Recurrence 56Leukemia 56Sarcoma 50Brain Neoplasms 50Lymphoma, Large B-Cell, Diffuse 48Carcinoma, Hepatocellular 47Lymphoma, Follicular 46

Interventions

siltuximab 1axicabtagene ciloleucel 1Interleukin 1 Receptor Antagonist Protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Cytokine Release Syndrome × 1 year × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡